The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

Shares of French speciality vaccines developer Valneva (Nasdaq: VAL) were down 8.4% at 2.89 euros by early afternoon, after ...

1 The chikungunya virus (CHIKV), an alphavirus, is the causative agent of this serious illness. To facilitate viral RNA replication, CHIKV creates distinctive organelles called spherules on the ...

Future Virology. 2008;3(2):179-192. Although not listed as a hemorrhagic fever virus, illness caused by CHIKV can be confused with diseases such as dengue or yellow fever, based on the similarity ...

updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ ® for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Bavarian Nordic's ...

Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash.

Now, in a recently released study of 117 children who were hospitalized between June and September 2024 (during the monsoon) ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendat ...

Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint ...